Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
300357 Zhejiang Wolwo Bio-Pharmaceutical
- 21.66
- +0.12+0.56%
Market Closed Dec 20 15:00 CST
11.34BMarket Cap36.34P/E (TTM)
21.80High21.43Low41.06KlotVolume21.50Open21.54Pre Close88.95MTurnover0.85%Turnover Ratio36.59P/E (Static)523.58MShares29.2152wk High4.80P/B10.48BFloat Cap16.3252wk Low25.85Limit Up484.06MShs Float97.15Historical High17.23Limit Down1.72%Amplitude3.12Historical Low0.19Dividend TTM21.66Avg Price21.08KlotAsk0.85%Div YieldTTM100Lot Size19.23KlotBid
Zhejiang Wolwo Bio-Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 8.38%730.24M | 11.12%429.26M | 18.08%216.25M | -5.34%848.19M | -3.77%673.79M | -0.67%386.3M | -7.31%183.14M | 10.94%896.02M | 12.98%700.18M | 11.88%388.9M |
| Operating revenue | 8.38%730.24M | 11.12%429.26M | 18.08%216.25M | -5.34%848.19M | -3.77%673.79M | -0.67%386.3M | -7.31%183.14M | 10.94%896.02M | 12.98%700.18M | 11.88%388.9M |
| Other operating revenue | ---- | 770.36%2.19M | ---- | 554.82%7.44M | ---- | -55.85%251.51K | ---- | -68.23%1.14M | ---- | -40.00%569.7K |
| Total operating cost | 14.36%427.57M | 15.08%265.41M | 19.37%132.39M | 5.48%513.94M | 5.30%373.88M | 9.67%230.62M | 2.59%110.91M | 11.25%487.24M | 13.44%355.06M | 9.08%210.29M |
| Operating cost | 11.86%34.63M | 11.33%21.69M | 8.24%10.42M | -2.64%40.19M | 1.14%30.96M | 17.93%19.48M | 17.47%9.62M | 19.86%41.28M | 20.07%30.61M | 9.55%16.52M |
| Operating tax surcharges | 46.07%4.66M | 61.87%3.5M | 47.54%1.29M | 26.96%5.76M | 2.71%3.19M | 11.74%2.16M | 12.34%876.35K | 19.98%4.53M | 17.16%3.1M | 14.22%1.94M |
| Operating expense | 11.61%270.79M | 10.96%163.44M | 16.25%80.96M | 3.64%323.17M | 6.42%242.62M | 9.48%147.29M | 3.85%69.64M | 10.53%311.81M | 10.95%227.99M | 6.33%134.54M |
| Administration expense | 29.84%52.76M | 28.30%33.65M | 28.53%16.46M | 29.87%62.11M | 17.02%40.63M | 28.36%26.23M | 17.56%12.8M | -7.78%47.82M | -1.49%34.72M | -7.31%20.43M |
| Financial expense | -5.07%-23.14M | -14.08%-16.12M | -13.23%-7.3M | -21.70%-29.48M | -24.46%-22.02M | -19.77%-14.13M | -13.77%-6.45M | -9.37%-24.23M | -5.31%-17.69M | -4.29%-11.8M |
| -Interest expense (Financial expense) | -1.76%899.57K | -5.94%619.42K | 19.02%319.26K | 194.70%1.31M | 267.75%915.71K | 354.48%658.57K | 235.20%268.23K | 22.57%443.98K | -9.31%249.01K | -25.62%144.91K |
| -Interest Income (Financial expense) | -5.22%-24.23M | -13.86%-16.9M | -15.15%-7.76M | -24.96%-30.96M | -27.77%-23.03M | -23.74%-14.85M | -16.68%-6.74M | -9.42%-24.77M | -4.99%-18.03M | -3.72%-12M |
| Research and development | 11.93%87.86M | 19.48%59.25M | 25.19%30.56M | 5.83%112.2M | 2.85%78.49M | 1.90%49.59M | -9.08%24.41M | 20.58%106.02M | 25.31%76.32M | 25.60%48.67M |
| Credit Impairment Loss | -66.87%-4.92M | -3,268.01%-2.47M | -2,967.77%-1.88M | 169.98%903.31K | 29.13%-2.95M | 109.20%78.07K | 109.88%65.63K | 19.07%-1.29M | 2.75%-4.16M | 54.71%-848.48K |
| Asset Impairment Loss | ---- | ---- | ---- | 98.94%-472.55K | ---472.55K | ---472.55K | ---- | ---44.4M | ---- | ---- |
| Other net revenue | 1,896.57%13.51M | 112.55%8.59M | 79.17%4.15M | 185.28%10.72M | -97.83%676.75K | -85.79%4.04M | -85.05%2.31M | -154.23%-12.57M | 155.46%31.25M | 121.35%28.42M |
| Fair value change income | 51.47%-763.41K | 102.49%30.18K | 140.75%400.18K | 24.25%-666.94K | -251.92%-1.57M | -272.34%-1.21M | -149.61%-982.13K | -783.37%-880.46K | -73.21%1.04M | -115.66%-325.52K |
| Invest income | 174.43%6.48M | -101.65%-53.11K | -114.74%-363.77K | -46.56%1.91M | -49.43%2.36M | -34.17%3.21M | 265.97%2.47M | -44.03%3.58M | 193.09%4.67M | 186.04%4.88M |
| -Including: Investment income associates | 204.81%3.99M | 46.00%-1.05M | 44.73%-434.53K | 14.06%-4.25M | -49.08%-3.8M | -65.60%-1.94M | -158.53%-786.13K | -159.16%-4.95M | -1,044.38%-2.55M | ---1.17M |
| Asset deal income | --568.93K | --353.47K | --284.61K | ---- | ---- | ---- | ---- | ---271.92K | ---271.92K | ---271.92K |
| Other revenue | 266.98%12.15M | 341.07%10.73M | 649.12%5.71M | -70.54%9.04M | -88.96%3.31M | -90.27%2.43M | -94.46%761.72K | 66.12%30.7M | 171.22%29.98M | 128.65%24.99M |
| Operating profit | 5.19%316.18M | 7.97%172.43M | 18.06%88.01M | -12.93%344.97M | -20.14%300.59M | -22.86%159.71M | -28.97%74.54M | 0.84%396.21M | 18.00%376.37M | 23.48%207.03M |
| Add:Non operating Income | -66.39%354.57K | -76.22%235.09K | -25.58%117.42K | -35.02%1.78M | -52.61%1.06M | -44.11%988.72K | -87.35%157.78K | 340.72%2.74M | -9.93%2.23M | -9.16%1.77M |
| Less:Non operating expense | 1,565.30%3.01M | 2,058.31%2.17M | 5,587.52%327.4K | 306.44%795.74K | 113.03%180.72K | 27.60%100.62K | -92.70%5.76K | -62.96%195.78K | -81.74%84.83K | -9.97%78.85K |
| Total profit | 4.00%313.52M | 6.16%170.5M | 17.54%87.8M | -13.24%345.96M | -20.36%301.46M | -23.06%160.6M | -29.61%74.7M | 1.46%398.75M | 17.93%378.52M | 23.12%208.72M |
| Less:Income tax cost | 22.42%51.03M | 47.60%27.88M | 80.84%13.88M | -19.98%50.43M | -30.06%41.68M | -41.85%18.89M | -55.25%7.67M | -5.53%63.02M | 9.01%59.6M | 18.41%32.48M |
| Net profit | 1.05%262.5M | 0.64%142.62M | 10.29%73.92M | -11.97%295.52M | -18.54%259.78M | -19.59%141.71M | -24.67%67.02M | 2.89%335.73M | 19.76%318.92M | 24.03%176.24M |
| Net profit from continuing operation | 1.05%262.5M | 0.64%142.62M | 10.29%73.92M | -11.97%295.52M | -18.54%259.78M | -19.59%141.71M | -24.67%67.02M | 2.89%335.73M | 19.76%318.92M | 24.03%176.24M |
| Less:Minority Profit | 5.89%-9.76M | 4.11%-6.61M | 4.81%-3.29M | -12.37%-14.66M | -24.91%-10.37M | -42.43%-6.89M | -25.00%-3.46M | -11.50%-13.05M | -0.00%-8.3M | 7.33%-4.84M |
| Net profit of parent company owners | 0.78%272.25M | 0.42%149.23M | 9.55%77.21M | -11.06%310.18M | -17.44%270.15M | -17.93%148.6M | -23.17%70.48M | 3.19%348.77M | 19.16%327.22M | 22.92%181.08M |
| Earning per share | ||||||||||
| Basic earning per share | 0.78%0.52 | 0.42%0.285 | 9.58%0.1475 | -11.06%0.5924 | -17.44%0.516 | -17.93%0.2838 | -23.17%0.1346 | 3.19%0.6661 | 19.18%0.625 | 22.89%0.3458 |
| Diluted earning per share | 0.78%0.52 | 0.42%0.285 | 9.58%0.1475 | -11.06%0.5924 | -17.44%0.516 | -17.93%0.2838 | -23.17%0.1346 | 3.19%0.6661 | 19.18%0.625 | 22.89%0.3458 |
| Other composite income | -117.52%-1.42K | 56,115.18%5.38M | 89,860.06%5.35M | -83.40%4.32K | -72.65%8.11K | -25.55%9.56K | -164.54%-5.96K | -99.90%26.03K | 1,087.55%29.66K | 483.80%12.84K |
| Other composite income of parent company owners | -117.52%-1.42K | 56,115.18%5.38M | 89,860.06%5.35M | -83.40%4.32K | -72.65%8.11K | -25.55%9.56K | -164.54%-5.96K | -99.90%26.03K | 1,087.55%29.66K | 483.80%12.84K |
| Total composite income | 1.04%262.5M | 4.43%148M | 18.28%79.26M | -11.98%295.53M | -18.55%259.79M | -19.59%141.72M | -24.67%67.01M | -4.68%335.75M | 19.77%318.95M | 24.04%176.26M |
| Total composite income of parent company owners | 0.78%272.25M | 4.03%154.61M | 17.15%82.56M | -11.07%310.19M | -17.45%270.16M | -17.94%148.61M | -23.18%70.47M | -4.16%348.8M | 19.18%327.25M | 22.93%181.09M |
| Total composite income of minority owners | 5.89%-9.76M | 4.11%-6.61M | 4.81%-3.29M | -12.37%-14.66M | -24.91%-10.37M | -42.43%-6.89M | -25.00%-3.46M | -11.50%-13.05M | -0.00%-8.3M | 7.33%-4.84M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
